Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Rating of “Moderate Buy” from Analysts

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) has been given an average rating of “Moderate Buy” by the six brokerages that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $30.00.

KYTX has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kyverna Therapeutics in a report on Friday, March 27th. Wall Street Zen lowered shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. HC Wainwright reiterated a “buy” rating and issued a $25.00 price target on shares of Kyverna Therapeutics in a report on Wednesday. Finally, JPMorgan Chase & Co. decreased their price target on shares of Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a report on Wednesday, May 13th.

Hedge Funds Weigh In On Kyverna Therapeutics

A number of hedge funds have recently made changes to their positions in KYTX. Public Employees Retirement System of Ohio purchased a new position in shares of Kyverna Therapeutics in the 3rd quarter valued at $28,000. Qube Research & Technologies Ltd purchased a new position in shares of Kyverna Therapeutics in the 2nd quarter valued at $43,000. Rhumbline Advisers raised its stake in shares of Kyverna Therapeutics by 22.0% in the 1st quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock valued at $61,000 after acquiring an additional 5,694 shares during the period. Ameriprise Financial Inc. purchased a new position in shares of Kyverna Therapeutics in the 3rd quarter valued at $77,000. Finally, Bank of America Corp DE raised its stake in shares of Kyverna Therapeutics by 41.6% in the 4th quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock valued at $81,000 after acquiring an additional 6,400 shares during the period. Institutional investors and hedge funds own 18.08% of the company’s stock.

Kyverna Therapeutics Stock Up 1.7%

Shares of KYTX opened at $7.95 on Friday. The firm has a market cap of $483.28 million, a PE ratio of -2.42 and a beta of 1.95. The company’s fifty day moving average is $9.03 and its two-hundred day moving average is $8.54. Kyverna Therapeutics has a fifty-two week low of $2.52 and a fifty-two week high of $13.67. The company has a quick ratio of 8.15, a current ratio of 8.15 and a debt-to-equity ratio of 0.13.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.66) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.09. Analysts forecast that Kyverna Therapeutics will post -2.78 earnings per share for the current year.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical?stage biotechnology company dedicated to developing engineered regulatory T?cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen?specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.